Fig. 1: Blockage of IFN-I activity by IFNAR1/2. | Nature Communications

Fig. 1: Blockage of IFN-I activity by IFNAR1/2.

From: Next generation of tumor-activating type I IFN enhances anti-tumor immune responses to overcome therapy resistance

Fig. 1

a Schematic depicting IFN-I binds to IFNAR1 and IFNAR2. b Design of IFN-I prodrug which IFNAR1/2 extracellular domain fused to IFN-Fc via a cleavable linker. c IFN activity of human IFNAR1/2 masked IFNa2b-Fc was assessed using a human IFN reporter cell line (n = 2). d IFN activity of mouse IFNAR1/2 masked IFNa4-Fc was assessed using mouse IFN reporter cell line (n = 2). e Reducing SDS-PAGE analysis of hProIFNa2b-Fc as well as MMP-14- or MMP-2-cleaved hProIFNa2b-Fc. The experiment was repeated two times independently with similar results. f IFN activity of MMP-activated hProIFNa2b-Fc, hIFNa2b-Fc, and hProIFNa2b-Fc was assessed via human IFN reporter cell line (n = 2). g Reducing SDS-PAGE analysis of mProIFNa4-Fc as well as MMP-14- or MMP-2-cleaved mProIFNa4-Fc. The experiment was repeated two times independently with similar results. h IFN activity of MMP-activated mProIFNa4-Fc, hIFNa2b-Fc, and mProIFNa4-Fc was assessed via mouse IFN reporter cell line (n = 2). Human IFN activity was assessed by 293T-Dual™ hSTING-R232 cells via secreted embryonic alkaline phosphatase activity. Mouse IFN activity was assessed by RAW-Lucia ISG cells via secreted coelenterazine-utilizing luciferase activity. Source data are provided as a Source Data file.

Back to article page